You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Immutep reveals commencement of vital phase 2 trial

Immutep – a company concentrating on novel LAG-3 immunotherapies for cancer and autoimmune conditions – has announced the beginning of an open-label phase 2 trial researching eftilagimod alpha (efti).